Instil Bio Reports $4.2 Million Net Loss in Q1 2026, Significant Expense Reductions Noted

Instil Bio, Inc. reported a net loss of $4.2 million for the first quarter of 2026, a significant reduction from the $28.2 million loss recorded in the same period of the previous year. This improvement is attributed to a substantial decrease in operating expenses, which fell to $7 million from $30.6 million year-over-year. The decline in expenses was primarily driven by reduced research and development costs, which decreased from $5.4 million to $0.7 million, following the discontinuation of the AXN-2510 program. General and administrative expenses also saw a reduction, dropping from $9.1 million to $5.3 million.

The company's total assets as of March 31, 2026, were approximately $200.4 million, a slight decrease from $203.5 million at the end of 2025. Cash and cash equivalents decreased to $5 million from $6.6 million, while marketable securities remained relatively stable at $69.5 million. The accumulated deficit increased to $730.7 million, reflecting the ongoing operational losses since the company's inception. Instil Bio's total liabilities were reported at $89.7 million, with a significant portion attributed to a loan payable of $85.6 million, which is due in January 2027.

In terms of strategic developments, Instil Bio's subsidiary, Axion Bio, terminated its collaboration agreement with ImmuneOnco in January 2026, resulting in a gain of $1.6 million recognized in the financial statements. The company is actively seeking to in-license or acquire new therapeutic candidates to address unmet medical needs. Additionally, the company has decided to discontinue the plan to sell its Tarzana facility, which had previously been classified as held for sale, and will reclassify it as held and used in the upcoming quarter.

Operationally, Instil Bio's employee headcount has been reduced as part of its restructuring efforts, which included the closure of its UK manufacturing facility and the termination of certain employees associated with the AXN-2510 program. The company is currently evaluating its financial position and plans to extend the maturity of its 2024 loan to January 2028, which may alleviate concerns regarding its ability to continue as a going concern. The company anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond 2027, although it acknowledges the need for additional financing to support future growth and development activities.